Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy

被引:65
作者
Isaacs, Joseph D. [1 ,2 ]
Shidiak, Louis [1 ,2 ]
Harris, Ian A. [3 ]
Szomor, Zoltan L. [2 ]
机构
[1] Univ New S Wales, Dept Orthopaed Surg, St George Hosp, Sydney, NSW 2217, Australia
[2] St George & Sutherland Hosp Orthopaed Dept, Sydney, NSW, Australia
[3] Univ New S Wales, Dept Orthopaed Surg, SW Sydney Clin Sch, Liverpool Hosp, Liverpool, NSW 2170, Australia
关键词
SUPPRESSED BONE TURNOVER; LONG-TERM ALENDRONATE; POSTMENOPAUSAL OSTEOPOROTIC WOMEN; INTERVENTION-TRIAL; MICRODAMAGE ACCUMULATION; BIOMECHANICAL PROPERTIES; RANDOMIZED-TRIAL; ORAL ALENDRONATE; MECHANICAL-PROPERTIES; VERTEBRAL FRACTURES;
D O I
10.1007/s11999-010-1535-x
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background Emerging evidence has linked the long-term use of bisphosphonates with femoral insufficiency fractures. It has been suggested that the prolonged effect on bone remodeling leads to the accumulation of microfractures and weakening of bone. Questions/purposes We investigated the association between bisphosphonate use and femoral insufficiency fractures. Methods We evaluated 100 patients with low-energy femoral shaft fractures before and after bisphosphonates became available for use. Twenty-one consecutive patients who presented between January 1995 and February 1997 were compared with 79 consecutive patients who presented between January 2007 and February 2009. The radiographs of all 100 patients were examined for evidence of preexisting insufficiency fractures. We identified insufficiency fractures by a transverse fracture line on the tension side of the femur with lateral cortical thickening immediately adjacent to the fracture. Relevant details from the history were recorded. Results Forty-one patients had an underlying femoral insufficiency fracture, all of whom had been receiving bisphosphonate therapy. Among the 21 patients with low-energy femoral fractures before the availability of bisphosphonates, none had insufficiency fractures. Of the 41 patients with insufficiency fractures, 29 (71%) had prodromal pain and 18 (44%) had bilateral insufficiency fractures. Bisphosphonate use was associated (odds ratio greater than 1000) with insufficiency fracture. The mean duration of bisphosphonate use in patients with insufficiency fractures was longer than in patients without fractures (7.1 versus 3.2 years). Conclusion Long-term bisphosphonate use is associated with insufficiency fractures of the femoral shaft, which commonly present with prodromal thigh pain and may be bilateral. These fractures were not seen before bisphosphonates became available for use.
引用
收藏
页码:3384 / 3392
页数:9
相关论文
共 68 条
[21]   Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday [J].
Curtis, J. R. ;
Westfall, A. O. ;
Cheng, H. ;
Delzell, E. ;
Saag, K. G. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (11) :1613-1620
[22]  
Dobnig H, 2009, J BONE MINER RES, V24, P1998, DOI [10.1359/JBMR.090527, 10.1359/jbmr.090527]
[23]   Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side? [J].
Edwards, M. H. ;
McCrae, F. C. ;
Young-Min, S. A. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (04) :701-703
[24]   Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension [J].
Ensrud, KE ;
Barrett-Connor, EL ;
Schwartz, A ;
Santora, AC ;
Bauer, DC ;
Suryawanshi, S ;
Feldstein, A ;
Haskell, WL ;
Hochberg, MC ;
Torner, JC ;
Lombardi, A ;
Black, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1259-1269
[25]   COMPARISON OF NEW BIOCHEMICAL MARKERS OF BONE TURNOVER IN LATE POSTMENOPAUSAL OSTEOPOROTIC WOMEN IN RESPONSE TO ALENDRONATE TREATMENT [J].
GARNERO, P ;
SHIH, WCJ ;
GINEYTS, E ;
KARPF, DB ;
DELMAS, PD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (06) :1693-1700
[26]   Subtrochanteric insufficiency fractures in patients on alendronate therapy - A caution [J].
Goh, S.-K. ;
Yang, K. Y. ;
Koh, J. S. B. ;
Wong, M. K. ;
Chua, S. Y. ;
Chua, D. T. C. ;
Howe, T. S. .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2007, 89B (03) :349-353
[27]   Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? [J].
Hirano, T ;
Turner, CH ;
Forwood, MR ;
Johnston, CC ;
Burr, DB .
BONE, 2000, 27 (01) :13-20
[28]   Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis [J].
Iwamoto, Jun ;
Takeda, Tsuyoshi ;
Sato, Yoshihiro .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) :919-928
[29]   Teriparatide Following Bisphosphonates: Initial and Long-Term Effects on Microarchitecture and Bone Remodeling at the Human Iliac Crest [J].
Jobke, Bjoern ;
Pfeifer, Michael ;
Minne, Helmut W. .
CONNECTIVE TISSUE RESEARCH, 2009, 50 (01) :46-54
[30]   Femoral Cortical Stress Lesions in Long-Term Bisphosphonate Therapy: A Herald of Impending Fracture? [J].
Koh, Joyce S. B. ;
Goh, Seo Kiat ;
Png, Meng Ai ;
Kwek, Ernest B. K. ;
Sen Howe, Tet .
JOURNAL OF ORTHOPAEDIC TRAUMA, 2010, 24 (02) :75-81